FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and Drug Safety & Risk Management Advisory Committee AGENDA January 30, 2009 The committees will discuss the safety and efficacy of propoxyphene and propoxyphene-combination products for the treatment of mild to moderate acute pain.					
			8:00 a.m.	Call to Order Introduction of Committee	John T. Farrar, M.D. Chair, ALSDAC
				Conflict of Interest Statement	Kalyani Bhatt Designated Federal Officer, ALSDAC/DSaRM
8:10 a.m.	Opening Remarks				
8:20 a.m.	Public Citizen Presentation	Public Citizen			
8:50 a.m.	Sponsor Presentations	Xanodyne Pharmaceuticals Qualitest/Vintage Pharmaceuticals			
10:05 a.m.	Break				
10:15 a.m.	Regulatory History and Clinical Efficacy of Propoxyphene Products				
10:30 a.m.	Clinical Pharmacology of Propoxyphene				
10:45 a.m.	Non-Clinical Toxicology Findings				
11:00 a.m.	Utilization Trends for Propoxyphene Products				
11:15 a.m.	Findings from AERS Analysis and Epidemiological Review of Cardiotoxicities Associated with Propoxyphene				
11:30 a.m.	Misuse/Abuse of Propoxyphene Products: Findings from The Drug Abuse Warning Network (DAWN)				

12:00 p.m Lunch

- 1:00 p.m. Open Public Hearing
- 2:00 p.m. Questions to the presenters
- 2:30 p.m. Discussion and Questions to the Committee

3:30 p.m. Adjourn

